1 / 29

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia. Panelists. Dallas Heart Study: Lipid Characteristics of African Americans With Nonsense Mutations in PCSK9. ARIC: PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk.

steffi
Télécharger la présentation

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

  2. Panelists

  3. Dallas Heart Study: Lipid Characteristics of African Americans With Nonsense Mutations in PCSK9

  4. ARIC: PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk

  5. SAR236553 Phase 2: Change in LDL-C at 4-Week Dosing Intervals on Atorvastatin

  6. MENDEL: AMG 145 Phase 2 Monotherapy in Patients With Hypercholesterolemia

  7. MENDEL: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

  8. LAPLACE-TIMI 57: Phase 2 AMG 145 in Combination With Statin in Patients With Hypercholesterolemia

  9. LAPLACE-TIMI 57: Study Design

  10. LAPLACE-TIMI 57: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

  11. LAPLACE-TIMI 57: Adverse Events

  12. GAUSS: Phase 2 AMG 145 in Statin-Intolerant Patients

  13. GAUSS: Baseline Characteristics

  14. GAUSS: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

  15. GAUSS: Percentage of Patients Achieving LDL-C Goals

  16. SAR236553 in Patients With Heterozygous FH on Statin Therapy With or Without Ezetimibe─Phase 2

  17. SAR236553: Change in LDL-C in Patients With Heterozygous FH on Statin Therapy With or Without Ezetimibe

  18. RUTHERFORD: Phase 2 AMG 145 in Patients With Heterozygous FH

  19. RUTHERFORD: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

  20. AMG 145: Ongoing Phase 2 Trials

  21. SAR236553 on Top of Atorvastatin in Primary Hypercholesterolemia: Phase 2

  22. Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy: Phase 2 Studies

  23. IV RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy: Doses Studied

  24. Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy: Pooled Results

  25. ODYSSEY Outcomes: Phase 3 Post-ACS With SAR236553

  26. Program Summary

  27. Thank you for participating in this activity.

More Related